<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Boycott Novartis &#187; Article</title>
	<atom:link href="http://novartisboycott.org/topics/article/feed/" rel="self" type="application/rss+xml" />
	<link>http://novartisboycott.org</link>
	<description>Campaign against the Swiss Pharmacuetical Company</description>
	<lastBuildDate>Fri, 27 Apr 2012 03:22:59 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>It&#8217;s a relief for the HIV-infected</title>
		<link>http://novartisboycott.org/its-a-relief-for-the-hiv-infected/</link>
		<comments>http://novartisboycott.org/its-a-relief-for-the-hiv-infected/#comments</comments>
		<pubDate>Wed, 09 Jul 2008 04:53:20 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Article]]></category>
		<category><![CDATA[TRIPS]]></category>

		<guid isPermaLink="false">http://novartisboycott.org/?p=36</guid>
		<description><![CDATA[Deccan Herald » Edit Page » Detailed Story IN PERSPECTIVE By Gopal Dabade Deccan Herald If patents are granted to a company, the price of the drug would be beyond the reach of the masses. Just a few days back &#8230; <a href="http://novartisboycott.org/its-a-relief-for-the-hiv-infected/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://novartisboycott.org/its-a-relief-for-the-hiv-infected/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Novartis may suffer jolt in Glivec case</title>
		<link>http://novartisboycott.org/novartis-may-suffer-jolt-in-glivec-case/</link>
		<comments>http://novartisboycott.org/novartis-may-suffer-jolt-in-glivec-case/#comments</comments>
		<pubDate>Thu, 21 Jun 2007 08:43:03 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Article]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Patent Litigation]]></category>
		<category><![CDATA[TRIPS]]></category>

		<guid isPermaLink="false">http://novartisboycott.org/novartis-may-suffer-jolt-in-glivec-case/</guid>
		<description><![CDATA[Financial Express, June 20, 2007 The Intellectual Property Appellate Board (IPAB), which has been formed to give a verdict on various patent cases across the country, may reject Novartis objection on the presence of S Chandrasekharan, the former patent controller, &#8230; <a href="http://novartisboycott.org/novartis-may-suffer-jolt-in-glivec-case/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://novartisboycott.org/novartis-may-suffer-jolt-in-glivec-case/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>If Novartis wins, other MNCs would also claim patents for well-known medicines</title>
		<link>http://novartisboycott.org/if-novartis-wins-other-mncs-would-also-claim-patents-for-well-known-medicines/</link>
		<comments>http://novartisboycott.org/if-novartis-wins-other-mncs-would-also-claim-patents-for-well-known-medicines/#comments</comments>
		<pubDate>Tue, 19 Jun 2007 12:25:46 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Article]]></category>
		<category><![CDATA[Campaign]]></category>

		<guid isPermaLink="false">http://novartisboycott.org/if-novartis-wins-other-mncs-would-also-claim-patents-for-well-known-medicines/</guid>
		<description><![CDATA[The case filed by the big pharmaceutical company Novartis has attracted global attention. &#8220;Doctors Without Borders&#8221; winner of the Nobel Prize for best medical relief in 1999, has requested people all over the world to write to the company to &#8230; <a href="http://novartisboycott.org/if-novartis-wins-other-mncs-would-also-claim-patents-for-well-known-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://novartisboycott.org/if-novartis-wins-other-mncs-would-also-claim-patents-for-well-known-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Solheim urges Novartis not to challenge Indian Patent Act</title>
		<link>http://novartisboycott.org/solheim-urges-novartis-not-to-challenge-indian-patent-act/</link>
		<comments>http://novartisboycott.org/solheim-urges-novartis-not-to-challenge-indian-patent-act/#comments</comments>
		<pubDate>Thu, 03 May 2007 08:31:42 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Article]]></category>
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://novartisboycott.org/solheim-urges-novartis-not-to-challenge-indian-patent-act/</guid>
		<description><![CDATA[THE HINDU, May 01, 2007 Norwegian Minister of International Development Erik Solheim has urged Novartis to withdraw its case against India, challenging a clause of the Indian Patent (Amendment) Act, which does not grant patents to medicines that are new &#8230; <a href="http://novartisboycott.org/solheim-urges-novartis-not-to-challenge-indian-patent-act/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://novartisboycott.org/solheim-urges-novartis-not-to-challenge-indian-patent-act/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Brief background of the Gleevec case</title>
		<link>http://novartisboycott.org/brief-background-of-the-gleevec-case/</link>
		<comments>http://novartisboycott.org/brief-background-of-the-gleevec-case/#comments</comments>
		<pubDate>Sat, 10 Mar 2007 10:33:26 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Article]]></category>
		<category><![CDATA[Campaign]]></category>
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://novartisboycott.org/brief-background-of-the-gleevec-case/</guid>
		<description><![CDATA[In 1997, Novartis AG filed a patent application in the Chennai ( Madras) Patent Controller&#8217;s office for the beta-crystalline of Imatinib Mesylate, brand name Glivec (Gleevec) on the ground that they invented the beta crystalline salt form (imatinib mesylate) of &#8230; <a href="http://novartisboycott.org/brief-background-of-the-gleevec-case/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://novartisboycott.org/brief-background-of-the-gleevec-case/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

